Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a pioneering biopharmaceutical company focused on the development of innovative therapies based on RNA interference (RNAi) technology. Founded in 2002, the company has established itself as a leader in the field of genetic medicine, aiming to address the underlying causes of diseases by silencing specific genes.

With a commitment to transforming the lives of patients, Alnylam’s research and development efforts are centred around rare genetic disorders, cardiovascular diseases, and infectious diseases. The company’s flagship product, ONPATTRO (patisiran), was the first-ever RNAi therapeutic approved for the treatment of hereditary transthyretin-mediated amyloidosis, marking a significant milestone in the industry.

Alnylam operates with a vision to create a new class of medicines that can provide effective treatments for patients with unmet medical needs. The company collaborates with various academic institutions, healthcare professionals, and other biopharmaceutical companies to advance its research initiatives and expand its pipeline of potential therapies.

• Innovative Technology: Alnylam leverages its proprietary RNAi platform to develop targeted therapies that can silence disease-causing genes.
• Patient-Centric Approach: The company prioritises patient needs and strives to deliver transformative therapies that improve quality of life.
• Global Reach: Alnylam is committed to making its therapies accessible to patients worldwide, working closely with regulatory agencies and healthcare systems.

Headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals continues to push the boundaries of science and medicine, driven by a mission to revolutionise the treatment landscape for patients suffering from serious diseases. With a robust pipeline and a dedicated team of experts, Alnylam is well-positioned to lead the next wave of innovation in biopharmaceuticals.